** Shares of Gain Therapeutics GANX.O down ~18% to $1.40 in extended trading on planned equity raise
** Bethesda, Maryland-based firm announces offering of stock and warrants
** It expects to use net offering proceeds to continue clinical/nonclinical development of its lead product candidate GT-02287 for treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease
** Newbridge Securities sole bookrunner for offering
** GANX on Tues closed down 8.6% at $1.70, down 21% YTD
** As of May 31, co had ~30.1 mln shares outstanding, per the prospectus
** All 7 analysts covering GANX are bullish and median PT is $8, latest LSEG data reflects
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。